Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 7:18:1163-1171.
doi: 10.2147/PPA.S459242. eCollection 2024.

Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis

Julia Sabin  1 , Elisa Salas  2 , Jesús Martín-Martínez  3 , Antonio Candeliere-Merlicco  4 , Francisco Javier Barrero Hernández  5 , Ana María Alonso Torres  6 , José Luis Sánchez-Menoyo  7 , Laura Borrega  8 , María Rodríguez-Rodríguez  9 , Montserrat Gómez-Gutiérrez  10 , Sara Eichau  11 , Miguel Ángel Hernández-Pérez  12 , Carmen Calles  13 , Eva Fernandez-Diaz  14 , Olga Carmona  15 , Aida Orviz  16 , Ana López-Real  17 , Pablo López-Muñoz  18 , Amelia Mendoza Rodríguez  19 , Eduardo Aguera-Morales  20 , Jorge Maurino  2
Affiliations

Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis

Julia Sabin et al. Patient Prefer Adherence. .

Abstract

Purpose: Shared decision-making is critical in multiple sclerosis (MS) due to the uncertainty of the disease trajectory over time and the large number of treatment options with differing efficacy, safety and administration characteristics. The aim of this study was to assess patients' decisional conflict regarding the choice of a disease-modifying therapy and its associated factors in patients with mid-stage relapsing-remitting multiple sclerosis (RRMS).

Methods: A multicenter, non-interventional study was conducted. Adult patients with a diagnosis of RRMS (2017 revised McDonald criteria) and disease duration of 3 to 8 years were included. The level of uncertainty experienced by a patient when faced with making a treatment choice was assessed using the 4-item Decisional Conflict Scale. A battery of patient-reported and clinician-rated measures was administered to obtain information on symptom severity, illness perception, illness-related uncertainty, regret, MS knowledge, risk taking behavior, preferred role in the decision-making process, cognition, and self-management. Patients were recruited during routine follow-up visits and completed all questionnaires online using electronic tablets at the hospital. A multivariate logistic regression analysis was conducted.

Results: A total of 201 patients were studied. Mean age (Standard deviation) was 38.7 (8.4) years and 74.1% were female. Median disease duration (Interquartile range) was 6.0 (4.0-7.0) years. Median EDSS score was 1.0 (0-2.0). Sixty-seven (33.3%) patients reported a decisional conflict. These patients had lower MS knowledge and more illness uncertainty, anxiety, depressive symptoms, fatigue, subjective symptom severity, a threatening illness perception, and poorer quality of life than their counterparts. Lack of decisional conflict was associated with MS knowledge (Odds ratio [OR]=1.195, 95% CI 1.045, 1.383, p=0.013), self-management (OR=1.049, 95% CI 1.013, 1.093, p=0.018), and regret after a healthcare decision (OR=0.860, 95% CI 0.756, 0.973, p=0.018) in the multivariate analysis.

Conclusion: Decisional conflict regarding the selection of a disease-modifying therapy was a common phenomenon in patients with mid-stage RRMS. Identifying factors associated with decisional conflict may be useful to implement preventive strategies that help patients better understand their condition and strengthen their self-management resources.

Keywords: decision-making; decisional conflict; disease-modifying therapies; disease-related knowledge; multiple sclerosis; self-management.

PubMed Disclaimer

Conflict of interest statement

Julia Sabin received honoraria for lecturing, consulting or travel expenses from Biogen, Merck, Teva, Novartis, BMS, Janssen, Almirall, Roche and Sanofi. Jesús Martín-Martínez served on scientific advisory boards and/or received speaking honoraria, research funding and support to attend scientific meetings from Biogen, Merck, Novartis, Roche and Teva. Francisco Javier Barrero received compensation for consulting services and speaking honoraria from Almirall, Biogen, Genzyme, Merck, Novartis, Roche, Sanofi and Teva. Ana Alonso received compensation for consulting services from Biogen, BMS, Sanofi, Roche, Janssen and Novartis; and speaking honoraria from Biogen, BMS, Sanofi, Roche, Janssen, Merck, Almirall and Novartis. José Luis Sánchez-Menoyo received support to attend scientific meetings from Novartis, Merck, and Biogen; speaking honoraria from Biogen, Novartis, Sanofi, Merck, Almirall, Bayer and Teva; and participated in clinical trials from Biogen, Merck and Roche. Laura Borrega received compensation for consulting services, speaking honoraria and support to attend scientific meetings from Bayer, Celgene, Biogen, Sanofi, Merck, Novartis, Roche, Almirall and Teva. Monserrat Gómez-Gutiérrez received honoraria as speaker from Biogen, BMS, Janssen, Merck, Mylan, Novartis, Roche, Sanofi and Bial. Sara Eichau received consulting fees and lecture honoraria from Biogen, Novartis, Sanofi, Merck, Roche and Almirall. Carmen Calles received compensation for consulting services, speaking honoraria and support to attend scientific meetings and courses from Merck, Teva, Sanofi, Novartis, Biogen, Roche, and BMS. Eva Fernández-Díaz received honoraria and travel expenses for participation in scientific meetings and advisory boards from Almirall, Biogen, Merck, Roche and Sanofi. Olga Carmona received honoraria for speaker services and advisory boards from Sanofi, Roche, Janssen and Merck. Aida Orvíz received research grants, travel support, advisory activities or honoraria for speaking engagements from Almirall, Biogen, BMS, Merck, Mylan, Novartis, Roche, Sanofi, and Teva. Ana López-Real received speaker and consultation fees, and congress travel support from Biogen, Janssen, Merck, Novartis, Roche and Sanofi. Amelia Mendoza received research grants, travel support or honoraria for speaking engagements from Biogen, Merck, Novartis, Roche, Sanofi, and Teva. Eduardo Agüera received speaking honoraria from Roche, Novartis, Merck, Sanofi and Biogen. Elisa Salas and Jorge Maurino are employees of Roche Farma Spain. The authors report no other conflicts of interest in this work.

Similar articles

  • Perceived illness-related uncertainty among patients with mid-stage relapsing-remitting multiple sclerosis.
    Sabin J, Salas E, Martín-Martínez J, Candeliere-Merlicco A, Barrero FJ, Alonso A, Sánchez-Menoyo JL, Borrega L, Rodríguez-Rodríguez M, Gómez-Gutiérrez M, Eichau S, Hernández-Pérez MÁ, Calles C, Fernández-Díaz E, Carmona O, Orviz A, López-Real A, López-Muñoz P, Mendonza A, Agüera E, Maurino J. Sabin J, et al. Mult Scler Relat Disord. 2024 Nov;91:105861. doi: 10.1016/j.msard.2024.105861. Epub 2024 Sep 3. Mult Scler Relat Disord. 2024. PMID: 39265268
  • Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis.
    Saposnik G, Andhavarapu S, Sainz de la Maza S, Castillo-Triviño T, Borges M, Barón BP, Sotoca J, Alonso A, Caminero AB, Borrega L, Sánchez-Menoyo JL, Barrero-Hernández FJ, Calles C, Brieva L, Blasco MR, García-Soto JD, Del Campo-Amigo M, Navarro-Cantó L, Agüera E, Garcés M, Carmona O, Gabaldón-Torres L, Forero L, Hervás M, García-Arcelay E, Terzaghi M, Gómez-Ballesteros R, Maurino J. Saposnik G, et al. Mult Scler Relat Disord. 2022 Dec;68:104138. doi: 10.1016/j.msard.2022.104138. Epub 2022 Aug 20. Mult Scler Relat Disord. 2022. PMID: 36029707
  • Long-term prognosis communication preferences in early-stage relapsing-remitting multiple sclerosis.
    Castillo-Triviño T, Gómez-Ballesteros R, Borges M, Martín-Martínez J, Sotoca J, Alonso A, Caminero AB, Borrega L, Sánchez-Menoyo JL, Barrero-Hernández FJ, Calles C, Brieva L, Blasco-Quílez MR, García-Soto JD, Del Campo-Amigo M, Navarro-Cantó L, Agüera E, Garcés-Redondo M, Carmona O, Gabaldón-Torres L, Forero L, Hervás M, Mauriño J, Sainz de la Maza S. Castillo-Triviño T, et al. Mult Scler Relat Disord. 2022 Aug;64:103969. doi: 10.1016/j.msard.2022.103969. Epub 2022 Jun 14. Mult Scler Relat Disord. 2022. PMID: 35728432
  • Shared Decision Making in Surgery: A Meta-Analysis of Existing Literature.
    Niburski K, Guadagno E, Abbasgholizadeh-Rahimi S, Poenaru D. Niburski K, et al. Patient. 2020 Dec;13(6):667-681. doi: 10.1007/s40271-020-00443-6. Patient. 2020. PMID: 32880820 Review.
  • Telephone interventions for symptom management in adults with cancer.
    Ream E, Hughes AE, Cox A, Skarparis K, Richardson A, Pedersen VH, Wiseman T, Forbes A, Bryant A. Ream E, et al. Cochrane Database Syst Rev. 2020 Jun 2;6(6):CD007568. doi: 10.1002/14651858.CD007568.pub2. Cochrane Database Syst Rev. 2020. PMID: 32483832 Free PMC article.
See all similar articles

References

    1. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: a Review. JAMA. 2021;325(8):765–779. doi:10.1001/jama.2020.26858 - DOI - PubMed
    1. Maurino J, Martínez-Ginés ML, García-Domínguez JM, et al. Workplace difficulties, health-related quality of life, and perception of stigma from the perspective of patients with Multiple Sclerosis. Mult Scler Relat Disord. 2020;41:102046. doi:10.1016/j.msard.2020.102046 - DOI - PubMed
    1. Sainz de la Maza S, Maurino J, Borges M, et al. Measuring productivity loss in early relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2022;58:103398. doi:10.1016/j.msard.2021.103398 - DOI - PubMed
    1. Morgan A, Tallantyre E, Ontaneda D. The benefits and risks of escalation versus early highly effective treatment in patients with multiple sclerosis. Expert Rev Neurother. 2023;23(5):433–444. - PubMed
    1. Singer BA, Feng J, Chiong-Rivero H. Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption. J Neurol. 2024. doi:10.1007/s00415-024-12305-4 - DOI - PMC - PubMed